We are live on ! Find out more
AXDX icon

Accelerate Diagnostics

Delisted

AXDX was delisted on the 14th of May, 2025.

72 hedge funds and large institutions have $18M invested in Accelerate Diagnostics in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.58% less ownership

Funds ownership: 27.34% → 25.76% (-1.6%)

13% less funds holding

Funds holding: 83 → 72 (-11)

36% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 22

54% less capital inflows, than outflows

Capital inflows: $2.23M | Capital outflows: $4.87M

65% less call options, than puts

Call options by funds: $52K | Put options by funds: $148K

80% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 15

100% less funds holding in top 10

Funds holding in top 10: 3 → 0 (-3)

Holders
72
Holders Change
-11
Holders Change %
-13.25%
% of All Funds
1.15%
Holding in Top 10
–
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-100%
% of All Funds
–
New
3
Increased
14
Reduced
22
Closed
15
Calls
$52​K
Puts
$148​K
Net Calls
-⁠$96​K
Net Calls Change
+$940​K

AXDX Hedge Fund Activity: Q4 2022 in Review

72 of the 6,238 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q4 2022, worth a combined $18M — down 56% from $41.2M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of AXDX and 3 opened new positions — a net loss of 12 holders — while 22 trimmed existing stakes and 14 added.

The largest buyer was Griffin Asset Management, adding an estimated $1.38M. The largest seller was 1492 Capital Management, exiting entirely with an estimated $684K sold.

  • 72 institutional investors held Accelerate Diagnostics (AXDX) as of Q4 2022, down from 83 in Q3 2022.
  • Funds reported $18M of Accelerate Diagnostics stock for Q4 2022, down 56% quarter-over-quarter.
  • 3 funds opened new Accelerate Diagnostics positions in Q4 2022 and 15 closed out, a net change of -12 holders.
  • The largest Accelerate Diagnostics buyer in Q4 2022 was Griffin Asset Management, an estimated $1.38M added.
  • The largest Accelerate Diagnostics seller in Q4 2022 was 1492 Capital Management, an estimated $684K sold.

Based on aggregated 13F filings for Q4 2022.